Command Palette

Search for a command to run...

Clinical Trials · NCT04232969

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

CompletedPhase 3Exenatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
University College, London
Enrollment
194
Start date
Jan 2020
Locations
1 site, United Kingdom
Primary endpoint
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3
View Exenatide compound reference